Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD

Bone Marrow Transplantation

Volumn 48, Issue 4, 2013, Pages 593-597

  Glotzbecker, B ^a   Ho, V T ^a   Aldridge, J ^a   Kim, H T ^a   Horowitz, G ^b   Ritz, J ^a   Soiffer, R ^a   Avigan, D ^b   Rosenblatt, J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

GVHD; hematopoietic SCT; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BUSULFAN; CALCIUM; CYCLOPHOSPHAMIDE; METHOTREXATE; MONOHYDROXYVITAMIN D; MULTIVITAMIN; TACROLIMUS; UNCLASSIFIED DRUG; VITAMIN D;

25 HYDROXYCOLECALCIFEROL BLOOD LEVEL; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ACUTE DISEASE; ADOLESCENT; ADULT; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VITAMIN D;

EID: 84876409982     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.177     Document Type: Article

References (50)

1. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
2. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
3. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 1.
4. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352.
5. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
6. Zhou Y, Zhou X, Wang X. 1, 25-Dihydroxyvitamin D3 prevented allergic asthma in a rat model by suppressing the expression of inducible nitric oxide synthase. Allergy Asthma Proc 2008; 29: 258-267.
7. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-7864.
8. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128: 68-72.
9. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1, 25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652.
10. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
11. Lemire JM, Archer DC, Khulkarni A, Ince A, Uskokovic MR, Stepkowski S. Prolongation of the survival of murine cardiac allografts by the vitamin D3 analogue 1, 25-dihydroxy-delta 16-cholecalciferol. Transplantation 1992; 54: 762-763.
12. Cutolo M, Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008; 17: 6-10.
13. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology 2008; 47: 840-848.
14. Chun RF, Adams JS, Hewison M. Back to the future: a new look at 'old' vitamin D. J Endocrinol 2008; 198: 261-269.
15. Svoren BM, Volkening LK, Wood JR, Laffel LM. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr 2009; 154: 132-134.
16. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612.
17. Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 2010; 133(Part 7): 1869-1888.
18. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S et al. 1, 25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in mye-loid but not plasmacytoid dendritic cells. J Immunol 2007; 178: 145-153.
19. Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, Daniel KC et al. Suppressive effect of 1alpha, 25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemo-taxis. J Immunol 2005; 174: 270-276.
20. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270: 701-708.
21. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired allo-reactive T cell activation. J Immunol 2000; 164: 2405-2411.
22. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443-4451.
23. Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K et al. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant 2010; 45: 1463-1468.
24. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 6800-6805.
25. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R et al. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-262.
26. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1141-1154.
27. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-58.
28. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012; 95: 91-100.
29. Sezer S, Yavuz D, Canoz MB, Ozdemir FN, Haberal M. Vitamin D status, bone mineral density, and inflammation in kidney transplantation patients. Transplant Proc 2009; 41: 2823-2825.
30. Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-444.
31. Ozdemir BH, Ozdemir AA, Sezer S, Colak T, Haberal M. Influence of 1, 25-dihy-droxyvitamin D3 on human leukocyte antigen-DR expression, macrophage infiltration, and graft survival in renal allografts. Transplant Proc 2011; 43: 500-503.
32. Sawinski D, Uribarri J, Peace D, Yao T, Wauhop P, Trzcinka P et al. 25-OH-vitamin D deficiency and cellular alloimmunity as measured by panel of reactive T cell testing in dialysis patients. Am J Transplant 2010; 10: 2287-2295.
33. Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 2003; 75: 2133-2134.
34. Courbebaisse M, Souberbielle JC, Thervet E. Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 2010; 89: 131-137.
35. van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
36. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003; 102: 3314-3316.
37. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39: 3147-3159.
38. Zhang AB, Zheng SS, Jia CK, Wang Y. Effect of 1, 25-dihydroxyvitamin D3 on preventing allograft from acute rejection following rat orthotopic liver transplantation. World J Gastroenterol 2003; 9: 1067-1071.
39. Hullett DA, Laeseke PF, Malin G, Nessel R, Sollinger HW, Becker BN. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005; 18: 1175-1186.
40. Cantorna MT, Hullett DA, Redaelli C, Brandt CR, Humpal-Winter J, Sollinger HW et al. 1, 25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 1998; 66: 828-831.
41. Mathieu C, Jafari M. Immunomodulation by 1, 25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol 2006; 66: 275-283.
42. Gorman S, Judge MA, Hart PH. Topical 1, 25-dihydroxyvitamin D3 subverts the priming ability of draining lymph node dendritic cells. Immunology 2010; 131: 415-425.
43. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138-151.
44. Tangpricha V, Turner A, Spina C, Decastro S, Chen TC, Holick MF. Tanning is associated with optimal vitamin D status (serum 25-hydroxyvitamin D concentration) and higher bone mineral density. Am J Clin Nutr 2004; 80: 1645-1649.
45. Lo CW, Paris PW, Clemens TL, Nolan J, Holick MF. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr 1985; 42: 644-649.
46. Akeno N, Matsunuma A, Maeda T, Kawane T, Horiuchi N. Regulation of vitamin D-1alpha-hydroxylase and-24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 2000; 164: 339-348.
47. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C et al. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 2011; 86: 954-956.
48. Urbain P, Ihorst G, Biesalski HK, Bertz H. Course of serum 25-hydroxyvitamin D(3) status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. Ann Hematol 2012; 91: 759-766.
49. Robien K, Strayer LG, Majhail N, Lazovich D, Baker KS, Smith AR et al. Vitamin D status among long-term survivors of hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 1472-1479.
50. Silva F, Perez-Simon JA, Caballero-Velazquez T, Sanchez-Guijo FM, Villanueva-Gomez F, Vazquez L et al. Effect of vitamin D treatment in chronic GVHD. Bone Marrow Transplant 2011; 46: 1395-1397.